Key Financial Figures (Quarter ended September 30, 2026)
Revenue from Operations: ₹100.83 crore
Other Income: -₹3.64 crore (negative)
Total Income: ₹97.19 crore
Total Expenses: ₹92.10 crore
Profit before Tax: ₹5.09 crore
Tax Expenses: ₹2.20 crore (Current Tax: ₹2.92 crore, Deferred Tax: -₹0.71 crore, Income Tax for earlier year: ₹0.00)
Net Profit for the Quarter: ₹2.88 crore
Total Comprehensive Income for the Quarter: ₹2.23 crore
Earnings Per Share (Basic & Diluted): ₹5.05
Key Financial Figures (Half Year ended September 30, 2026)
Revenue from Operations: ₹202.17 crore
Other Income: ₹24.32 crore
Total Income: ₹226.49 crore
Total Expenses: ₹185.60 crore
Profit before Tax: ₹40.88 crore
Tax Expenses: ₹6.01 crore (Current Tax: ₹6.47 crore, Income Tax for earlier year: -₹2.35 crore, Deferred Tax: ₹1.88 crore)
Net Profit for the Half Year: ₹34.88 crore
Total Comprehensive Income for the Half Year: ₹33.20 crore
Earnings Per Share (Basic & Diluted): ₹61.11
Comparative Figures (Quarter ended September 30, 2025)
Revenue from Operations: ₹87.24 crore
Net Profit/(Loss): -₹3.30 crore (Loss)
Earnings Per Share (Basic & Diluted): -₹5.79 (Loss)
Balance Sheet Highlights (as of September 30, 2026, Unaudited)
Total Assets: ₹553.54 crore
Total Equity: ₹421.88 crore
Equity Share Capital: ₹5.71 crore
Other Equity: ₹416.18 crore
Total Liabilities: ₹131.66 crore
Cash Flow Statement (Half Year ended September 30, 2026)
Net Cash from Operating Activities: ₹9.40 crore
Net Cash used in Investing Activities: -₹6.91 crore
Net Cash from Financing Activities: ₹0.60 crore
Net Increase in Cash and Equivalents: ₹3.08 crore
Closing Cash and Cash Equivalents: ₹3.41 crore
Other Material Information
Dividend: The company paid a dividend of ₹5.00 per equity share (face value ₹10/-) during the quarter, pertaining to FY ended March 31, 2026. The total outflow was ₹2.85 crore.
Segment Information: The company is engaged solely in the manufacturing of pharmaceuticals, constituting one reportable segment.
Board Meeting: The meeting was held on November 12, 2026, commencing at 11:00 AM and concluding at 01:00 PM.
Audit Review: The statutory auditors, L.B. Jha & Co., LLP, issued an unmodified limited review report on the unaudited financial results, stating nothing came to their attention to believe the statement contains any material misstatement.
